Existing and Emerging Strategies in the Management of Patients with Uterine Sarcomas

CME Information

TARGET AUDIENCE
This activity is intended for gynecologic oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

OVERVIEW OF ACTIVITY
As a group, gynecologic sarcomas are relatively rare, and given their wide heterogeneity, specific histologic subtypes present even less frequently in clinical practice. As such, gynecologic and medical oncologists may lack experience managing any given uterine sarcoma. Even so, and despite the fact that conventional treatment options for sarcomas of the female genital tract had remained unchanged for several years, recently published research has led to several newly FDA-approved therapies poised to disrupt established standards. With the proliferation of these research advances it is important for any healthcare professional involved in the care of these individuals to remain up to date in order to appropriately offer patients uterine sarcoma high-quality care.

These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2017 Annual Meeting on Women’s Cancer feature discussions with leading researchers with expertise in gynecologic oncology and/or sarcoma management. Using a blend of practical perspectives and review of clinical trial data, this activity is designed to address many of the most pertinent issues and education gaps faced by clinicians managing this unusual, challenging and heterogeneous disease.

LEARNING OBJECTIVES
- Appreciate the importance of multidisciplinary collaboration in the diagnosis and management of uterine sarcomas, and use this information to design a process to optimize tissue procurement, accurate histological assessment, tertiary care referral and treatment outcome.
- Apply evidence-based research findings in the formulation of treatment strategies for Stage I to III uterine sarcoma, considering the potential contributions of surgery, radiation therapy and/or cytotoxic therapy.
- Develop an understanding of the mechanism of action, available clinical trial data and FDA-approved indication for olaratumab.
- Appraise available safety and efficacy data with olaratumab, pazopanib and trabectedin for patients with advanced uterine sarcomas, and consider how these agents can be optimally incorporated in current clinical management algorithms.
- Communicate with patients regarding the incidence and manifestation of side effects and toxicities associated with commonly used systemic agents/ regimens in the management of uterine sarcomas to actively include these individuals in shared decision-making and properly prepare them for future treatment.
- Recall new data with other investigational agents demonstrating promising activity in patients with uterine sarcomas.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement.
We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

**HOW TO USE THIS CME ACTIVITY**

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GynOnc17/Sarcoma/CME.

**CONTENT VALIDATION AND DISCLOSURES**

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Suzanne George, MD**  
Clinical Director  
Center for Sarcoma and Bone Oncology  
Senior Physician  
Associate Professor of Medicine  
Harvard Medical School  
Dana-Farber Cancer Institute  
Boston, Massachusetts

Consulting Agreement: AstraZeneca Pharmaceuticals LP;  
Conducted Research: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Deciphera Pharmaceuticals, Novartis, Pfizer Inc.

**David Scott Miller, MD**  
Amy and Vernon E Faulconer Distinguished Chair in Medical Science  
Dallas Foundation Chair in Gynecologic Oncology  
Professor and Chief  
Division of Gynecologic Oncology  
Department of Obstetrics and Gynecology  
Harold C Simmons Comprehensive Cancer Center  
UT Southwestern Medical Center  
Dallas, Texas

Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Conducted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Takeda Oncology; Speakers Bureau: Genentech BioOncology.

**Bradley J Monk, MD**  
Professor and Director  
Division of Gynecologic Oncology  
Vice Chair, Department of Obstetrics and Gynecology  
University of Arizona Cancer Center — Phoenix  
Creighton University School of Medicine at Dignity Health St Joseph's Hospital and Medical Center  
Phoenix, Arizona


**Brian A Van Tine, MD, PhD**  
Assistant Professor of Medicine  
Department of Medicine at Washington University  
St Louis, Missouri

Advisory Committee: Caris Life Sciences, EMD Serono Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Novartis; Conducted Research: Eisai Inc, Merck, Pfizer Inc; Paid Research: Eisai Inc, Merck; Speakers Bureau: Caris Life Sciences, GlaxoSmithKline, Novartis.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

This activity is supported by an educational grant from Lilly.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2017
Expiration date: August 2018
David Scott Miller, MD


Brian A Van Tine, MD, PhD

Tap WD et al. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). Proc ASCO 2015;Abstract 10501.

Bradley J Monk, MD


Seddon BM et al. GeDDis: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). Proc ASCO 2015;Abstract 10500.